Twist Bioscience Co. (NASDAQ:TWST) Insider Patrick John Finn Sells 2,702 Shares

Twist Bioscience Co. (NASDAQ:TWST) insider Patrick John Finn sold 2,702 shares of Twist Bioscience stock in a transaction on Monday, April 5th. The shares were sold at an average price of $126.72, for a total transaction of $342,397.44. Following the completion of the sale, the insider now directly owns 43,102 shares in the company, valued at approximately $5,461,885.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of NASDAQ TWST opened at $127.64 on Thursday. The firm has a 50-day simple moving average of $131.27 and a 200-day simple moving average of $127.75. The stock has a market capitalization of $6.21 billion, a price-to-earnings ratio of -34.04 and a beta of 0.83. Twist Bioscience Co. has a 52 week low of $25.72 and a 52 week high of $214.07.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Wednesday, February 3rd. The company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. The firm had revenue of $28.16 million for the quarter, compared to analyst estimates of $25.26 million. Twist Bioscience had a negative net margin of 155.31% and a negative return on equity of 44.62%. Equities research analysts expect that Twist Bioscience Co. will post -3.03 earnings per share for the current fiscal year.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Twist Bioscience from a “sell” rating to a “hold” rating in a report on Thursday. JPMorgan Chase & Co. cut Twist Bioscience from a “neutral” rating to an “underweight” rating and set a $100.00 price objective on the stock. in a report on Friday, February 5th. Finally, Robert W. Baird increased their target price on Twist Bioscience from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, February 5th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $110.50.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. BlackRock Inc. increased its position in shares of Twist Bioscience by 11.8% during the 4th quarter. BlackRock Inc. now owns 3,499,004 shares of the company’s stock worth $494,375,000 after purchasing an additional 370,176 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Twist Bioscience by 14.5% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,850,717 shares of the company’s stock valued at $261,488,000 after purchasing an additional 234,339 shares during the last quarter. Nikko Asset Management Americas Inc. raised its position in Twist Bioscience by 13.9% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 1,840,306 shares of the company’s stock valued at $260,017,000 after purchasing an additional 223,928 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Twist Bioscience by 48.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 970,977 shares of the company’s stock worth $137,189,000 after buying an additional 317,301 shares during the period. Finally, Credit Suisse AG grew its stake in shares of Twist Bioscience by 1,743.6% in the fourth quarter. Credit Suisse AG now owns 846,581 shares of the company’s stock valued at $119,613,000 after buying an additional 800,661 shares in the last quarter. Institutional investors and hedge funds own 87.90% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Article: Using other technical indicators with support levels

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.